PO.CH02.02 · 化学

全面的表面组分析揭示骨肉瘤中的肿瘤特异性靶点

Comprehensive surfaceome profiling reveals tumor specific targets in osteosarcoma

海报缩略图:全面的表面组分析揭示骨肉瘤中的肿瘤特异性靶点
编号 7666 展板 20 时间 4/22 09:00–12:00 区域 Section 38 主讲 Snehal Ganjave, PhD
分会场 Multi-Omics, Systems Biology, and Biological Mass Spectrometry
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Snehal D. Ganjave1, Kevin K. Leung1, Leanne C. Sayles2, Alejandro Sweet-Cordero1, James A. Wells3

1UCSF - University of California San Francisco, San Francisco, CA,2Lab Manager, Pediatrics Cancer Biology, University of California, San Francisco, CA,3UCSF Comprehensive Cancer Ctr., San Francisco, CA

摘要 Abstract

中文摘要
骨肉瘤(OS)是一种以显著基因组改变为特征的侵袭性骨癌。尽管近期在研究OS方面付出了努力,但由于富集低丰度表面蛋白的技术限制,异种移植模型中驱动肿瘤发生和转移的胞外蛋白仍研究不足。在此,我们通过麦胚凝集素(WGA)-HRP介导的细胞表面蛋白富集,采用定量表面组分析来绘制原发性和转移性OS的动态表面蛋白格局,发现了临床上可操作的靶点。我们应用了一种整合的蛋白质组学方法,将基于WGA-HRP的细胞表面捕获与深度离线肽段分级、联用DIA-PASEF质谱相结合,以实现深度且准确的表面组覆盖。原发性和转移性OS细胞系(n = 9)和PDX肿瘤(n = 4-5),连同对照(n = 3),使用WGA-HRP介导的表面富集,随后进行基于Neutravidin的下拉分析。PDX肿瘤经机械解离以获得单细胞悬液。富集的蛋白经离线分级,并使用高pH分级和DDA-PASEF生成深度谱库,实现了跨多样样本对OS表面组的高分辨率定量绘图。优化后的工作流程共鉴定出约6,000种蛋白,其中超过600种通过Surfy数据库验证为可成药的表面蛋白(FDR < 0.01)。PCA显示样本按疾病状态和表型清晰分离,证明了表面组谱的高重现性和生物学保真度。所有转移性OS细胞系与对照的比较分析鉴定出大量高度失调的表面蛋白(log₂FC ≥ 5)。表面组谱揭示了已报道的和新的靶点,包括对增强营养物质转运和代谢重编程至关重要的蛋白、关键的细胞间黏附和结构维持分子以及突出的生长信号受体的显著且协调的上调。这些上调的功能类别与增强的转移能力和侵袭性肿瘤进展密切相关。这些发现提供了OS重塑的全面表面组图谱,揭示了相互关联的、肿瘤特异性的失调和可操作的表面靶点。所鉴定的蛋白类别突显了用于早期诊断、预后和监测治疗反应的潜在生物标志物,并可指导靶向生物制剂和免疫疗法的合理开发,以改善OS患者的预后。 致谢:本项目由美国卫生与公众服务部(HHS)FDA的OCE作为一项财政援助奖励的一部分予以支持[授予UCSF的CERSI资助,U01FD005978],总额为1,257,392美元。内容为作者的观点,不必然代表FDA/HHS或美国政府的官方立场,亦不构成其认可。
查看英文原文 English abstract
Osteosarcoma (OS) is an aggressive bone cancer characterized by significant genomic alterations. Despite recent efforts to study OS, the extracellular proteins driving tumorigenesis and metastasis in xenograft models remain understudied due to technical limitations in enriching low-abundance surface proteins. Here, we employed quantitative surfaceome profiling via Wheat Germ Agglutinin (WGA)-HRP mediated cell surface protein enrichment to map the dynamic surface protein landscape of primary and metastatic OS, uncovering clinically actionable targets. We applied an integrated proteomics approach combining WGA-HRP-based cell surface capture and deep offline peptide fractionation coupled with DIA-PASEF mass spectrometry to achieve deep and accurate surfaceome coverage. Primary and metastatic OS cell lines (n = 9) and PDX tumors (n = 4-5), along with controls (n = 3), were analyzed using WGA-HRP mediated surface enrichment followed by Neutravidin based pulldown. PDX tumors were mechanically dissociated to obtain single suspensions. Enriched proteins were fractionated offline, and a deep spectral library was generated using high-pH fractionation and DDA-PASEF, enabling high-resolution, quantitative mapping of the OS surfaceome across diverse samples. The optimized workflow identified ~6,000 total proteins, of which over 600 were validated as druggable surface proteins through Surfy database (FDR < 0.01). PCA revealed clear separation of samples by disease state and phenotype, demonstrating the high reproducibility and biological fidelity of the surfaceome profiles. Comparative analysis of all metastatic OS cell lines vs. controls identified numerous highly dysregulated surface proteins (log₂FC ≥ 5). The surfaceome profile revealed both reported & novel targets, including a pronounced and coordinated upregulation of proteins critically involved in enhanced nutrient transport and metabolic reprogramming, key cell-cell adhesion and structural maintenance molecules, and prominent growth signaling receptors. These upregulated functional classes are critically implicated in enhanced metastatic capacity and aggressive tumor progression. These findings provide a comprehensive surfaceome map of OS remodelling, revealing interconnected, tumor-specific dysregulation and actionable surface targets. The identified protein classes highlight potential biomarkers for early diagnosis, prognosis, and monitoring therapeutic response, and can guide the rational development of targeted biologics and immunotherapies to improve outcomes for OS patients. Acknowledgement: This project is supported by the OCE, FDA of the U.S. Dept of Health and Human Services (HHS) as part of a financial assistance award [CERSI grant to UCSF, U01FD005978] totaling $1,257,392. The contents are those of the author(s) & do not necessarily represent the official views of, nor an endorsement by FDA/HHS, or the U.S. Govt.
利益披露 Disclosure
S. D. Ganjave, None.. K. K. Leung, None.

← 返回 AACR 2026 检索